Mild Behavioral Impairment (MBI) describes the emergence of later-life Neuropsychiatric Symptoms (NPS) as an at-risk state for cognitive decline and dementia and as a potential manifestation of prodromal dementia. How NPS mechanistically link to the development of Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) is not fully understood.
Introduction
Neuropsychiatric symptoms (NPS) are common to all types of neurocognitive disorders and are linked to poorer quality of life, more rapid functional decline, added disease burden, greater healthcare costs and higher rates of mortality 1 . There is increasing acknowledgment that NPS form an intrinsic aspect of prodromal dementia and may be an early marker of cognitive decline that can precede or accompany the onset of cognitive symptoms and clinical diagnosis Table 1 ). These loci are clustered in biological pathways that are play an important role in the development of cognitive impairment and dementia, and are involved in the accumulation of the neuropathological features (amyloid beta (Aβ) and neurofibrillary tangles) of LOAD. The neuropathological features of LOAD have also been associated with greater impairment over time in NPS, and depression specifically, in cognitively normal and demented subjects [14] [15] [16] .
As such, LOAD risk loci may also be associated with the development of NPS, though, at present the role of LOAD risk loci in the development of NPS is unclear. Most research to date has focused on the association of APOE with individual NPS, with associations observed for depression, anxiety, apathy, delusions/hallucinations and agitation/aggression 17 . However, contrasting findings have been observed between studies on the association between APOE and affective symptoms (depression and anxiety), while there is limited cross-sectional evidence to suggest an association between apathy, agitation/aggression and delusions/hallucinations that has not been replicated in longitudinal studies 17 . To our knowledge, no study has examined the role of non-APOE LOAD risk loci with the development of NPS.
Here we report the associations of 24 genome-wide significant LOAD risk loci, either individually or collectively as a genetic risk score, with MBI in 1,226 sub-clinical and nondemented community dwelling adults.
Methods

Participants
Participants of this study were community dwelling older adults who were recruited into a longitudinal study of health and wellbeing, the Personality and Total Health Through Life project (PATH). The background and test procedures for PATH have been described in detail elsewhere 18 . We used data from the PATH Wave 4 60+ cohort. 
Cognitive Function and Clinical Diagnosis
The diagnostic procedure used to determine cognitive function states and clinical diagnoses 19 . Individuals who did not meet any of the above criteria were classified as cognitively normal.
Informant Interview
Informants were nominated by the PATH participant and provided information on the participant's physical and mental health via a telephone interview. Informants were predominantly spouses (49.4%), children (33.8%), or a close friend (9.7%) 2 . The informant interview included the Neuropsychiatric Inventory (NPI) 22 , to assesses the presence and severity of dementia related behavioural symptoms, over one month, in 10 neuropsychiatric domains (delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity) and two neurodegenerative domains (night-time behavioural disturbances and appetite and eating abnormalities).
Mild Behavioral Impairment
The Importantly, these domains reflect areas of NPS shown to be valid and related to the syndromes of cognitive decline.
MBI was assessed in accordance with Criterion 1 of the ISTAART-AA diagnostic criteria for MBI 23 , but with a reference range of one month, using the Neuropsychiatric Inventory (NPI) 22 . 
SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 and CASS4;
Supplementary Table 1) were genotyped using TaqMan OpenArray assays as previously described 25, 26 , in addition to the two SNPs defining the APOE alleles which were genotyped using TaqMan assays as previously described 27 . All SNPs were in Hardy-Weinberg equilibrium and genotype frequencies are reported in Supplementary Table 2 .
For the genetic risk score analysis SNPs were coded additively according to the number of risk alleles, whereas for the single SNP analysis variants were coded additively according to the number of minor alleles (Supplementary Table 1 ). The APOE *ε2 and APOE *ε4 alleles were assumed to be dominant to the APOE *ε3 allele. APOE alleles were coded as APOE *ε2+ (APOE *ε2/ε3 + APOE *ε2/ε2), APOE *ε4+ (APOE *ε4/ε3 + APOE *ε4/ε4) or APOE *ε3/ε3. Participants with the APOE *ε2/ε4 allele were excluded to avoid conflation between the APOE *ε2 protective and APOE *ε4 risk effects.
Using the LOAD risk SNPs, an OR weighted genetic risk score (OR-GRS) was constructed, which is the sum of all the risk alleles across the individual, weighted by the Odds Ratio 28 .
The OR-GRS is calculated according to the following formula:
for the ith patient, where
= the log of the odds ratio for the jth SNP and ‫ܩ‬ = the number of risk alleles for jth SNP. GRS were not calculated for individuals with missing genetic data (n = 93). We weighted the LOAD risk SNPs using the previously reported OR for LOAD (Supplementary Table 1 ). As APOE is known to have the largest effect size for LOAD, the OR-GRS was also calculated excluding APOE to determine the effect of the GRS beyond that of APOE. The OR-GRS was transformed into a z-score.
Data analysis
All analysis was performed in the R 3.3.2 Statistical computing environment. The association of the LOAD GRS with MBI domains was examined using logistic regression models adjusting for age, gender and years of education. Individual SNPs were similarly assessed, with each model only including a single SNP. Because 25 loci (APOE ε2, APOE ε4, & 23 LOAD GWAS SNPs) and one GRS were tested, p < 0.0019 was considered to be study wide significant after Bonferroni correction. p < 0.05 and >0. 0019 was considered nominally significant.
As a sensitivity analysis, the above models were re-run 1) with cognitive status included as a covariate and 2) with CN-AR and MCI participants excluded.
Results
Population characteristics of the PATH cohort
Descriptive characteristics of the wave 4 PATH cohort are presented in 
Association of AD related genetic variants with MBI
A binomial logistic regression was performed to evaluate the effects of the OR-GRS on the likelihood of participants exhibiting MBI symptoms (Table 2 ). Increasing OR-GRS was associated with an increased likelihood of exhibiting Affective Dysregulation, with a 1SD
increase having a 1.23 higher odds (p = 0.0047). However, when APOE was excluded from the OR-GRS, it was no longer significantly associated with any of the MBI domains. We further evaluated the effects of the individual SNPs on MBI, the observed associations would not withstand correction for multiple testing and we report the results that were nominally significant ( Table 2) Supplementary Table 3 . These results are largely non-significant and would not withstand correction for multiple testing.
Including cognitive status as a covariate in the models did not markedly change the results (Supplementary Table 4 ) for the association of the AD genetic loci with MBI. When assessing the associations in CN participants only (Supplementary Table 5 ), the results were largely similar, though some differences were observed, with ZCWPW1*C no longer associated with Abnormal Perception/Thought Control; FERMT2*C been associated with a decreased risk of impulse dyscontrol and; HLA-DRB1*T associated with an increased risk of impulse dyscontrol and Abnormal Perception/Thoughts.
Discussion
In this study, we investigated the association of genome-wide significant LOAD risk loci with MBI symptoms in a large cohort of cognitively normal and sub-clinical participants. We Dysregulation. However, this association was attenuated when APOE was excluded from the GRS, indicating that the association was driven by the dominant effect of the APOE*ε4
allele. The majority of these findings, however, were nominally significant (p < 0.05 and >0. 0019), with only the APOE -affective dysregulation association significant after multiple testing (p = 0.0018).
The association between APOE and depression in population based studies and in dementia patients has been widely investigated in the literature, however, the results between studies are mixed 17, 29 . A recent meta-analysis including 13 studies of late-life depression found that the APOE ε4 allele significantly increased risk of depression 30 . Furthermore, a longitudinal population based analysis found that the APOE ε4 allele was associated with incident minor depression and depression symptom severity over 5 years, even after excluding participants who developed dementia within 9 years 29 . The results from our analysis provide additional support for APOE promoting increased risk of late-life depression, though further longitudinal analysis is needed to verify these findings. This additional analysis is needed as it remains unclear whether depression is a risk factor of AD and dementia or an early manifestation of AD brain pathology 1 .
The mechanisms underlying the increased risk of depression in APOE ε4 carriers are not fully understood, with several potential mechanisms been implicated. First, brain atrophy may act as an intermediating factor, with APOE e4 carriers exhibiting greater medial temporal lobe atrophy 31 . Temporal lobe atrophy has also been associated an increased risk of incident major depression independently of dementia 32 . Second, APOE is associated with cerebrovascular dysfunction 33 , while late-life depression is associated with increased cerebrovascular comorbidities and microvascular lesions 34 . This suggests that cerebrovascular dysfunction induced by the APOE ε4 may increase cerebrovascular damage leading to increased depressive symptoms. Third, APOE influences amyloid-β (Aβ) aggregation, deposition and clearance, with the ε4 allele associated with increased Aβ levels and plaque burden 31 . Increased Aβ levels have also been associated with depression and worsening depressive symptoms over time 14, 35 . This maybe driven by a neuroinflammatory response as a result of microglial activation by Aβ 36 , promoting the release of inflammatory cytokines that interferes with neurotransmitters and neurocircuitry, leading to depressive symptoms 37 .
In addition to APOE, two SNPs within the MS4A locus were associated with a decreased risk of affective dysregulation. The function of the proteins encoded by the genes within the MS4A gene cluster is not well characterized, however recent reports have suggested a putative role in the immune system by promoting activation of microglia and the release of pro-inflammation of cytokines [38] [39] [40] . Inflammation impacts the synaptic availability of the monoamines serotonin, noradrenaline and dopamine, as well as the excitatory amino acid glutamate, that can ultimately affect the neurocircuitry that regulates behavior associated with anhedonia and anxiety, core aspects of depression 37 . As such, the MS4A putative role in the immune system may influence both AD pathology and depressive symptoms.
BIN1 and EPHA1 were both associated with the MBI domain abnormal perception/thought control. In AD patients with psychosis (AD + P), neuroimaging and post-mortem data have indicated an exaggerated prefrontal cortical synaptic deficit 41 . Greater synapse loss in AD + P maybe a result of either increased accumulation of pathology in AD + P or from enhanced synaptic vulnerability to these pathology due to other molecular changes 41 . In agreement with this, tau pathology has been consistently shown to be increased in AD + P 41, 42 . The association between BIN1 and tau pathology has been firmly established, where BIN1
knockdown in a Drosophila model suppressed tau-mediated neurotoxicity, while in human neuroblastoma cell lines and the mouse brain BIN1 and tau were observed to colocalize and interact 43 . Accordingly, BIN1 has been associated increased neurofibrillary tangle burden 44 .
The results from this analysis suggests that BIN1 may influence tau pathological burden, promoting synaptic loss and the development of psychotic symptoms within the prodromal phase of dementia. The role of EPHA1 in AD is not well understood, however, it is highly expressed in the adult brain and plays a role in synaptic formation and plasticity, axonal guidance and brain development [45] [46] [47] . This suggests that variants in EPHA1 may enhance synaptic vulnerability to AD pathology, and corresponding psychotic symptoms. However, these results should be interpreted with caution. A recent genome wide association study of AD + P did find that both BIN1 and EPHA1 were associated with AD + P when contrasting to controls, however no association was observed when contrasting AD + P to AD -P 48 . This suggests that both loci are associated with AD irrespective of psychotic symptoms, though this analysis did have limited power.
Finally, we observed a decreased risk for NME8 with decreased motivation and ZCWPW1
with a decreased risk of social inappropriateness and abnormal perception/thought control.
The role of NME8 and ZCWPW1 in AD is not well characterised, with both loci relatively understudied 49 . NME8 has been previously associated with non-neurological related diseases 50 , and recently with cognitive decline, elevated CSF tau and hippocampal atrophy 50 .
The pathophysiology of apathy in AD is characterised by dysfunctions in the prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, amygdala and basal ganglia, particularly in regard to cortico-subcortical circuits involving dopaminergic and cholinergic pathways 51, 52 . As with NME8, the function of ZCWPW1 is unknown, though the index SNP was shown to have functional evidence as an expression quantitative trait locus for PILRB, which is expressed in microglia and is involved in the regulation of immune response 53 . The neurobiological correlates of disinhibition in AD include Orbitofrontal-subcortical circuit dysfunction, that impairs social cognitive abilities and loss of control over reactions 52, 54 . Due to the scarcity of studies investigating the role of NME8 and ZCWPW1, the possible underlying mechanisms for their associations with the MBI domains are not known.
The results from this study should be interpreted in conjunctions with some study limitations.
First, as this is a candidate gene study, which can be subject to false positive findings, further replication of our results is needed in an independent cohort. Second, MBI was assessed using the NPI rather than the recently published MBI checklist. The NPI rating scales are designed to assess neuropsychiatric symptoms in dementia, and as such might not be sensitive to milder symptomology in functionally independent community dwelling adults 23 .
Additionally, the NPI assesses neuropsychiatric symptoms over a short reference time periods that maybe confounded by transient reactive states (e.g. sleep deprivation, medications, adversity) when used in the context of prodromal states 23 . Third, as the NPS are assessed via informants, the neuropsychiatric data maybe susceptible to recall bias, influenced by the informants mood, cultural beliefs, denial or education 55 . Finally, as the neuropsychiatric data were only collected at wave 4 in PATH, we are unable to conduct longitudinal analysis to assess whether the AD risk loci are associated with progression in NPS. Despite these limitations, this study had several strengths, including consisting of a large population based sample, inclusion of all the known GWAS LOAD risk loci and the narrow age-range reduces the influence of age differences on the results.
In conclusion, this is the first study to investigate the association of LOAD genetic risk loci with MBI. We found that five LOAD risk loci (APOE, MS4A, BIN1, EPHA1, NME8 and ZCWPW1) are associated with MBI domains. Nevertheless, the results from this study need to be replicated in independent cohorts to validate our findings, as the APOE -affective dysregulation association is the only test to survive correction for multiple testing. These findings suggest a common genetic etiology between MBI and traditionally recognized memory problems observed in dementia/AD and improve our understanding of the pathophysiological features underlying MBI. 
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